{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"80.5","upperLimit":"100","value":"100"},{"groupId":"OG001","lowerLimit":"87.2","upperLimit":"100","value":"100"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"27"}],"units":"Participants"}],"description":"Percentage of participants with hematopoietic engraftment post-transplant. Engraftment is defined as the first day absolute neutrophil counts exceeded 0.5 X 10\\^9/ml.","dispersionType":"95% Confidence Interval","groups":[{"description":"Subjects will receive transplant conditioning with Ara-C, Cyclophosphamide, Campath-1H, Total Body Irradiation and will then receive T cell depleted stem cell infusion processed by the CLINIMACS Device\n\nAra-C: day-8 through day-5\n\n3 g/m2 q 12 hours\n\nCyclophosphamide: day-7 and day-6\n\n45 mg/kg\n\nCampath-1H: day-3 through day-1\n\nDosing for children:\n\n5 - 15kg : 3mg IV in 30ml NS\n\n15.1 - 30kg : 5mg IV in 50ml NS\n\n\\>30 kg : 10mg IV in 100ml NS\n\nAdults will receive 10mg IV in 100ml NS\n\nTotal Body Irradiation: day-4 through day-1\n\n175 cGy x 2 at 24 cGy/min\n\nStem Cell Infusion: Stem cells are infused on day 0","id":"OG000","title":"CLINIMACS Device"},{"description":"Subjects will receive transplant conditioning with Ara-C, Cyclophosphamide, Campath-1H, Total Body Irradiation and will then receive T cell depleted stem cell infusion processed by the ISOLEX Device\n\nAra-C: day-8 through day-5\n\n3 g/m2 q 12 hours\n\nCyclophosphamide: day-7 and day-6\n\n45 mg/kg\n\nCampath-1H: day-3 through day-1\n\nDosing for children:\n\n5 - 15kg : 3mg IV in 30ml NS\n\n15.1 - 30kg : 5mg IV in 50ml NS\n\n\\>30 kg : 10mg IV in 100ml NS\n\nAdults will receive 10mg IV in 100ml NS\n\nTotal Body Irradiation: day-4 through day-1\n\n175 cGy x 2 at 24 cGy/min\n\nStem Cell Infusion: Stem cells are infused on day 0","id":"OG001","title":"ISOLEX Device"}],"paramType":"NUMBER","populationDescription":"A participant is evaluable for engraftment if the participant underwent transplant and either completed 28 days observation or engrafted. Of the 46 participants at baseline, one in CLINIMACS group did not undergo transplant and one in ISOLEX group died 5 days after transplant.Thus, 2 participants were not included in the analysis.","reportingStatus":"POSTED","timeFrame":"28 days","title":"Engraftment Rate After Transplant","type":"PRIMARY","unitOfMeasure":"percentage of participants"}